Literature DB >> 25660156

Should FOLFOXIRI plus bevacizumab Be the standard first-line therapy in metastatic colorectal cancer?

Ryan D Nipp1, David P Ryan2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25660156      PMCID： PMC4350810          DOI： 10.1634/theoncologist.2014-0495

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  21 in total

1.  Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines.

Authors:  Anthony D Yang; Fan Fan; E Ramsay Camp; George van Buren; Wenbiao Liu; Ray Somcio; Michael J Gray; Haiyun Cheng; Paulo M Hoff; Lee M Ellis
Journal:  Clin Cancer Res       Date:  2006-07-15       Impact factor: 12.531

2.  Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy.

Authors:  Scott Kopetz; George J Chang; Michael J Overman; Cathy Eng; Daniel J Sargent; David W Larson; Axel Grothey; Jean-Nicolas Vauthey; David M Nagorney; Robert R McWilliams
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544

3.  Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale.

Authors:  Giuseppe Colucci; Vittorio Gebbia; Giancarlo Paoletti; Francesco Giuliani; Michele Caruso; Nicola Gebbia; Giacomo Cartenì; Biagio Agostara; Giuseppe Pezzella; Luigi Manzione; Nicola Borsellino; Andrea Misino; Sante Romito; Ernesto Durini; Stefano Cordio; Marisa Di Seri; Massimo Lopez; Evaristo Maiello; Severino Montemurro; Antonio Cramarossa; Vito Lorusso; Maurizio Di Bisceglie; Maurizio Chiarenza; Maria Rosaria Valerio; Teresa Guida; Vita Leonardi; Salvatore Pisconti; Gerardo Rosati; Francesco Carrozza; Giuseppe Nettis; Matteo Valdesi; Gianfranco Filippelli; Santo Fortunato; Sergio Mancarella; Cosimo Brunetti
Journal:  J Clin Oncol       Date:  2005-06-06       Impact factor: 44.544

4.  Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database.

Authors:  Qian Shi; Aimery de Gramont; Axel Grothey; John Zalcberg; Benoist Chibaudel; Hans-Joachim Schmoll; Matthew T Seymour; Richard Adams; Leonard Saltz; Richard M Goldberg; Cornelis J A Punt; Jean-Yves Douillard; Paulo M Hoff; Joel Randolph Hecht; Herbert Hurwitz; Eduardo Díaz-Rubio; Rainer Porschen; Niall C Tebbutt; Charles Fuchs; John Souglakos; Alfredo Falcone; Christophe Tournigand; Fairooz F Kabbinavar; Volker Heinemann; Eric Van Cutsem; Carsten Bokemeyer; Marc Buyse; Daniel J Sargent
Journal:  J Clin Oncol       Date:  2014-11-10       Impact factor: 44.544

5.  Participation of patients 65 years of age or older in cancer clinical trials.

Authors:  Joy H Lewis; Meredith L Kilgore; Dana P Goldman; Edward L Trimble; Richard Kaplan; Michael J Montello; Michael G Housman; José J Escarce
Journal:  J Clin Oncol       Date:  2003-04-01       Impact factor: 44.544

6.  Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates.

Authors:  G Folprecht; A Grothey; S Alberts; H-R Raab; C-H Köhne
Journal:  Ann Oncol       Date:  2005-05-03       Impact factor: 32.976

7.  Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.

Authors:  Alfredo Falcone; Sergio Ricci; Isa Brunetti; Elisabetta Pfanner; Giacomo Allegrini; Cecilia Barbara; Lucio Crinò; Giovanni Benedetti; Walter Evangelista; Laura Fanchini; Enrico Cortesi; Vincenzo Picone; Stefano Vitello; Silvana Chiara; Cristina Granetto; Gianfranco Porcile; Luisa Fioretto; Cinzia Orlandini; Michele Andreuccetti; Gianluca Masi
Journal:  J Clin Oncol       Date:  2007-05-01       Impact factor: 44.544

8.  Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Authors:  Leonard B Saltz; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Jim Cassidy
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

9.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

10.  Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.

Authors:  Eric Van Cutsem; Claus-Henning Köhne; Erika Hitre; Jerzy Zaluski; Chung-Rong Chang Chien; Anatoly Makhson; Geert D'Haens; Tamás Pintér; Robert Lim; György Bodoky; Jae Kyung Roh; Gunnar Folprecht; Paul Ruff; Christopher Stroh; Sabine Tejpar; Michael Schlichting; Johannes Nippgen; Philippe Rougier
Journal:  N Engl J Med       Date:  2009-04-02       Impact factor: 91.245
View more
  2 in total

1.  Risk and management of venous thromboembolisms in bevacizumab-treated metastatic colorectal cancer patients.

Authors:  Irene Yu; Leo Chen; Jenny Y Ruan; Jennifer T Chang; Winson Y Cheung
Journal:  Support Care Cancer       Date:  2015-08-19       Impact factor: 3.603

Review 2.  A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer.

Authors:  Fotios Loupakis; Alexander Stein; Marc Ychou; Frank Hermann; Antonieta Salud; Pia Österlund
Journal:  Target Oncol       Date:  2016-06       Impact factor: 4.493
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.